Camposol 1Q 2024 Earnings Conference Call Unsecured notes due 2027





May 2024

Disclaimer



This presentation does not provide full disclosure of all material facts relating to Camposol Holding PLC and its direct or indirect subsidiaries, including but not limited to Camposol S.A., a sociedad anónima organized under the laws of Peru (together, the "Company" or "Camposol"), the securities of Camposol or a potential offering of such securities and is not subject to liability for misrepresentations under applicable securities legislation.

The contents hereof should not be construed as investment, legal, tax or other advice and you should consult your own advisers as to legal, business, tax and other related matters concerning an investment in Camposol

This presentation does not constitute a prospectus and should under no circumstances be understood as an offer to sell or the solicitation of an offer to buy securities nor will there be any sale of securities in any state, province or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Such an offer or solicitation can only be made by way of an effective registration statement or prospectus in accordance with the securities laws.

Certain statements herein are "forward-looking statements." Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "plans," "project," "target," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "potential," "can," "may," or the negative of these terms or similar expressions are generally intended to identify forward-looking statements. These forward-looking statements speak only as of the date hereof and are based on Camposol's current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond Camposol's control. As a consequence, current plans, anticipated actions and future financial position and results of operations may differ significantly from those expressed in any forward-looking statements in the presentation. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented and we do not intend to update any of these forward-looking statements.

No representation or warranty is given in respect of the information contained herein, and neither the delivery of this presentation nor any investment in Camposol securities will under any circumstances create any implication that Camposol has updated the information contained herein. Information throughout the presentation provided by sources other than Camposol has not been independently verified. Differences between past performance and actual results may be material and adverse.

This presentation includes unaudited non-IFRS financial measures, including Adjusted EBITDA and Adjusted EBITDA Margin. We present non-IFRS measures when we believe that the additional information is useful and meaningful to investors. Non-IFRS financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-IFRS financial measures is not intended to be a substitute for, and should not be considered in isolation from, the financial measures reported in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board.

Neither this presentation nor the information contained herein may be copied, reproduced, disclosed or distributed in whole or in part at any time without the prior written consent of Camposol. By accepting this presentation, the recipient acknowledges and agrees that this presentation and all of the information contained herein is confidential and subject to the confidentiality email previously acknowledged by the recipient. Without limiting the generality of the foregoing, the recipient will not reproduce this presentation in whole or in part and will hold all information contained in this presentation and the fact that Camposol is considering a potential initial public offering in confidence.

Speakers Today




Ricardo Naranjo Fernandez CFO

Jossue Yesquen Lihim IRO

Operational Overview

Annex






- The first quarter of 2024 marked a period of exceptional performance for Camposol, as we achieved record-breaking results in our company's history.
- Efforts to control cost continued, building on the achievements of 2023. By the end of 1Q 2024, we implemented new initiatives yielding an additional savings, including procurement renegotiations, optimizations in Colombian avocado operations, mandarin processing in Uruguay, among others.
- Debt restructuring initiatives continued in 1Q 2024. Reducing short-term debt by USD 22 million, executing bond repurchases resulting in an additional USD 12.5 million reduction in nominal value, and diligently servicing leasebacks.
- The experience gained in blueberry management over these years has enabled us to develop our own blueberry variety. Currently, we have 50 hectares planted with our variety, and in 1Q, we began the project of replanting an additional 200 hectares.

Operational Overview

Annex

Operational overview 1Q 2024 - Key metrics





Volume sold by the end of the first quarter of 2024 shows an 11.1% decrease compared to the same period last year, mainly driven by declines in the volume of mangoes and grapes, offset by a higher volume sold of blueberries.


Revenue at the close of the first quarter of 2024 experienced a remarkable 28.9% increase compared to the same period last year. Notably, blueberries emerged as the top performer, followed by mangoes, reinforcing our diverse and thriving portfolio.

The EBITDA performance at the close of the first quarter in 2024 showcases an impressive surge of 119.1% compared to the corresponding period last year. Remarkably, within the initial three months of 2024, our EBITDA nearly matches that of our entire performance in 2022

The net profit generated in the first quarter of 2024 has already surpassed the total net profit generated throughout the year 2023. This achievement is attributed not only to the successful cost control initiatives implemented in 2023 and new initiatives that led to additional savings in 2024, but also to a very effective commercial strategy.


Operational overview 1Q 2024 - Global footprint






Operational overview 1Q 2024 - Crop performance






9

Operational overview 1Q 2024 - Crop performance LTM



Operational overview 1Q 2024 - Quarterly EBITDA reconciliation





The EBITDA performance at the close of the first quarter in 2024 showcases an impressive surge of 119.1% compared to 1Q 23. Remarkably, in 1Q 24, EBITDA nearly matches that of our entire performance in 2022.

Blueberry : Achieved margin growth despite market price normalization trends from Peru and ongoing Chilean campaign through coordinated field operations, distribution, and direct retailer engagement.

Mango: Despite Peruvian production decline, Camposol showcased resilience and adaptability, mitigating reduced sales volume through efficient irrigation, which contributed to securing favorable market prices

Selling expenses: The decrease, particularly in freight costs which saw a 39% reduction compared to 1Q 23, is primarily attributed to the improved average freight rate and lower volume.



Operational overview 1Q 2024 - Cash flow



The collection in 1Q 2024 set a record for a first quarter, marking the strongest first quarter collection in recent years. This effect is directly linked to the blueberry and mango campaigns. Additionally, we received a payment of USD 1.1 million from a loan granted to related companies. These funds were prioritized for supplier payments and limited capex disbursements. This allowed us to continue with our company's total debt reduction plan.


Capex include the completion of the first stage of our water reservoir at the Agricultor Farm and the commencement of the second stage. We are continuing the hectare replanting process, with plans to replant 200 hectares of blueberries this year using our proprietary variety.



Operational overview 1Q 2024 - Leverage and Debt profile


Debt Profile

In the first quarter of 2024, efforts towards debt restructuring persisted. Short-term debt was reduced by USD 22 million; bond repurchases were undertaken leading to an extra USD 12.5 million reduction in nominal value, and leasebacks were diligently serviced.



Total financing credit lines vs short term debt

- Available credit line Working capital short term debt
- Available credit line / WKSTD



During 2022, we encountered significant cash pressure, leading to heightened reliance on our short-term credit facilities with financial institutions. In 2023, we initiated efforts to mitigate this dependency by reducing our exposure to short-term debt and expanding the available capacity within our financing credit lines. These efforts continued throughout 1Q 2024, and as a result, we now have greater flexibility and enhanced capability to manage our short-term debt obligations effectively.




Operational overview 1Q 2024 - Leverage and Debt profile




Debt history

Currently, we have a debt structure with reduced short-term concentration. Our relationship with financial institutions remains strong due to the close collaboration and work we conduct with them.



Net Debt / EBITDA



Prioritizing debt reduction, alongside margin enhancements, yielded a Net Debt/EBITDA ratio of 3.37x. This underscores the company's commitment to bolstering financial stability through proactive debt management measures





Operational Overview

Annex

Financial Statements - Income Statement

camposo_

	For the period ended	
	31.03.2024	31.03.2023
Revenue	152,039	117,960
Cost of sales	(85,363)	(78,727)
Gross profit before adjustment for biological assets	66,676	39,233
Net adjust. from change in fair value of Bio. Assets	-	(6,371)
Profit after adjustment from biological assets	66,676	32,862
Selling expenses	(13,905)	(19,647)
Administrative expenses	(5,576)	(5,076)
Other expenses	(975)	(969)
Other income	1,444	271
Net foreign exchange transactions gains (losses)	(1,956)	(1,218)
Operating profit	45,708	6,223
Share of gain (loss) of associated companies	-	597
Finance income	3,428	102
Finance costs	(11,032)	(10,827)
Profit (loss) before income tax	38,104	(3,905)
Income tax	(6,043)	(1,532)
Deferred income tax	3,921	2,016
Profit (loss) for the period	35,982	(3,421)
TDA before fair value adjustment	60,407	27,566

Financial Statements - Balance Sheet

For the period and od



	For the pe	For the period ended		
	31.03.2024	31.12.2023		
Assets			Ec	
Non-current assets			Ca	
Property, plant and equipment, net	737,029	740,801	sh	
Right of use asset	34,846	36,379	Sh	
Investments in associated companies	4,852	4,852	Re	
Intangibles	12,325	12,885	Re	
Deferred income tax	18,853	14,014		
Other accounts receivable	408	408	M	
	808,313	809,339	То	
Current assets			No	
Assets held for sale	-	-	Lc	
Prepaid expenses	918	1,126	Le	
Current portion of biological assets	165,106	165,106	De	
Inventories	49,609	50,922	01	
Other accounts receivable	30,027	32,166		
Trade accounts receivable	21,563	45,303	Cı	
Cash subject to restriction	-	-	Ac	
Cash and cash equivalents	25,854	23,903	Сι	
	293,077	318,526	С	
Total assets	1,101,390	1,127,865	τ	

	For the period ended		
	31.03.2024	31.12.2023	
Equity and liabilities			
Capital and reserve attributable to			
shareholders of the Company			
Share capital	10,000	10,000	
Revaluation of assets	172,497	172,497	
Retained earnings	153,506	118,490	
	336,003	300,987	
Minority interests	- 993	- 994	
Total equity	335,010	299,993	
Non-current liabilities			
Long-term debt	333,948	346,639	
Lease liability	63,989	70,261	
Deferred income tax	124,084	123,166	
Other payables	1,398	1,398	
	523,419	541,464	
Current liabilities			
Accounts payable to related companies	31	31	
Current portion of long-term debt	3,852	8,562	
Current portion of lease liability	20,078	22,130	
Trade payables	89,396	103,756	
Other payables	26,967	27,168	
Bank loans	102,637	124,761	
	242,961	286,408	
Total liabilities	766,380	827,872	
Total equity and liabilities	1,101,390	1,127,865	







Búscanos como CamposolCares en:



Búscanos como Camposol en:

in

Para más información por favor conectarse a: www.camposol.com.pe

For more information please log into: www.camposol.com.pe